Economic Evaluation of Alternative Strategies to Treat Patients with Diabetes Mellitus and Coronary Artery Disease

American Journal of Cardiology

Volumn 97, Issue 12 SUPPL., 2006, Pages 59-65

  Hlatky, Mark A ^a   Melsop, Kathryn A ^a   Boothroyd, Derek B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

ACUTE CORONARY SYNDROME; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DIABETES MELLITUS; DRUG ELUTING STENT; ECONOMIC EVALUATION; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART CATHETERIZATION; HEART INFARCTION SIZE; HEART MUSCLE REVASCULARIZATION; HOSPITAL BILLING; HUMAN; HYPERTENSION; MEDICARE; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REIMBURSEMENT; SELF MONITORING; TRANSLUMINAL CORONARY ANGIOPLASTY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; COST BENEFIT ANALYSIS; ECONOMICS; INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL REVASCULARIZATION; RANDOMIZED CONTROLLED TRIALS; UNITED STATES;

EID: 33745226169     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.03.014     Document Type: Article

References (23)

1. Mark D.B., and Hlatky M.A. Medical economics and the assessment of value in cardiovascular medicine. part I. Circulation 106 (2002) 516-520
2. Mark D.B., and Hlatky M.A. Medical economics and the assessment of value in cardiovascular medicine. part II. Circulation 106 (2002) 626-630
3. Meltzer M.I. Introduction to health economics for physicians. Lancet 358 (2001) 993-998
4. Russell L.B., Gold M.R., Siege J.E., Daniels N., Weinstein M.C., and Panel on Cost-Effectiveness in Health and Medicine. The role of cost-effectiveness analysis in health and medicine. JAMA 276 (1996) 1172-1177
5. Mark D.B., Cowper P.A., Berkowitz S.D., Davidson-Ray L., DeLong E.R., Turpie A.G.G., Califf R.M., Weatherly B., and Cohen M. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. results from the ESSENCE randomized trial. Circulation 97 (1998) 1702-1707
6. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
7. Diabetes Control and Complications Trial Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 18 (1995) 1468-1478
8. Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 276 (1996) 1409-1415
9. Testa M.A., and Simonson D.C. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus. JAMA 280 (1998) 1490-1496
10. Wagner E.H., Sandhu N., Newton K.M., McCulloch D.K., Ramsey S.D., and Grothaus L.C. Effect of improved glycemic control on health care costs and utilization. JAMA 285 (2001) 182-189
11. Gray A., Raikou M., McGuire A., Fenn P., Stevens R., Cull C., Stratton I., Adler A., Holman R., and Turner R. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes. economic analysis alongside randomised controlled trial (UKPDS 41). BMJ 320 (2000) 1373-1378
12. The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287 (2002) 2542-2551
13. Grover S.A., Coupal L., Zowall H., and Dorais M. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes. who should be treated?. Circulation 102 (2000) 722-727
14. Yusuf S., Zucker D., Peduzzi P., Takaro T., Fisher L., Kennedy J., Davis K., Killip T., and Norris R. Effect of coronary artery bypass graft surgery on survival. overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 344 (1994) 563-570
15. Weinstein M.C., and Stason W.B. Cost-effectiveness of coronary artery bypass surgery. Circulation 66 (1982) III-56-III-66
16. Wong J.B., Sonnenberg F.A., Salem D.N., and Pauker S.G. Myocardial revascularization for chronic stable angina. analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med 113 (1990) 852-871
17. Sculpher M.J., Petticrew M., Kelland J.L., Elliott R.A., Holdright D.R., and Buxton M.J. Resource allocation for chronic stable angina. a systematic review of effectiveness, costs and cost-effectiveness of alternative interventions. Health Technol Assess 2 (1998) i-iv 1-176
18. Bucher H.C., Hengstler P., Schindler C., and Guyatt G.H. Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease. meta-analysis of randomised controlled trials. BMJ 321 (2000) 73-77
19. Sculpher M., Smith D., Clayton T., Henderson R., Buxton M., Pocock S., and Chamberlain D. Coronary angioplasty versus medical therapy for angina. health service costs based on the second Randomized Intervention Treatment of Angina (RITA-2) trial. Eur Heart J 23 (2002) 1291-1300
20. Favarato D., Hueb W., Gersh B.J., Soares P., Cesar L., Protasio L., Oliveira S., and Ramires J. Relative cost comparison of treatments for coronary artery disease. the first year follow-up of MASS II study. Circulation 108 suppl 2 (2003) II-21-II-23
21. Hlatky M.A., Rogers W.J., Johnstone I., Boothroyd D., Brooks M.M., Pitt B., Reeder G., Ryan T., Smith H., Whitlow P., et al. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. N Engl J Med 336 (1997) 92-99
22. Hlatky M.A., Boothroyd D.B., Melsop K.A., Brooks M.M., Mark D.B., Pitt B., Reeder G.S., Rogers W.J., Ryan T.J., Whitlow P.L., and Wiens R.D. Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease. Circulation 110 (2004) 1960-1966
23. Melsop K., Boothroyd D.B., and Hlatky M.A. Quality of life and utility in patients with coronary artery disease. Am Heart J 145 (2003) 36-41